Healthcare -
Biotechnology - NASDAQ - US
$ 3.35
0.601 %
$ 2.33 M
Market Cap
0.0
P/E
Price Target
Average
--100.00%
Revenue Forecast
Estimate
-0.00%
EBIT
Estimate
25.99%
Net Income
Estimate
81.84%
WALL STREET ESTIMATES
Wall Street Analysts Price Targets
TransCode Therapeutics, Inc.
RNAZ has no price targets from Wall Street.
REVENUE FORECAST
Revenue Forecast Chart RNAZ
EBIT FORECAST
EBIT Forecast Chart RNAZ
NET INCOME FORECAST
Net Income Chart RNAZ